Amgen's D-mab: The New EPO

D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.

D-mab is the new EPO. At least, that’s what Amgen Inc. is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Submitted to FDA in December 2008 (and in the EU in January 2009) for post-menopausal osteoporosis (PMO) and some cancer indications, this drug is what Amgen needs if there’s to be independent life after its eroding EPO franchise, opines Jonas Alsenas, an analyst at Leerink Swann (which makes a market in Amgen). (See "Can Amgen Find a New Engine?" IN VIVO, May 2007 Also see "Can Amgen Find a New Engine?" - In Vivo, 1 May, 2007..)

According to Roger Perlmutter, MD, PhD, Amgen’s EVP, R&D, there’s no question that Amgen will have D-mab, though. Despite the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from In Vivo Archive

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

New Identifying The Barriers For Use Of Digital Clinical Trial Technologies

Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.

Nesw Fewer Acquisitions And Alliances In 2023, But Valuations Increased

 
• By 

INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.

Publisher’s Spotlight: Citeline News And Insights App

 
• By 

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.